• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Rogers Corporation

Rogers Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results

    Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results

  2. Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

    Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

  3. Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

    Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

  4. Chugai Announces License Agreement for Recycling Antibody SA237

    Chugai Announces License Agreement for Recycling Antibody SA237

  5. Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma

    Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma

  6. New Cancer Drugs: First Movers Will Win

    First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.

  7. Wide-Moat Funds That Fly Under the Radar

    These quality funds with smaller asset bases have portfolios built around solid companies.

  8. Funds Betting on Big Pharma

    Large drugmakers are out of favor, but some good funds are banking on a rebound.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.